Integrated Filing — IndAS



General information about company

Scrip Code 532296
NSE Symbol GLENMARK
MSEI Symbol NOTLISTED
ISIN INE935A01035
Name of company Glenmark Pharmaceuticals Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 29-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 19-05-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment PHARMACEUTICALS
Start date and time of board meeting 29-05-2026   16:30:00
End date and time of board meeting 29-05-2026   19:26:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 14-02-2025
Indicate Company website link for updated RPT policy of the Company https://glenmark.b-cdn.net/gpl_pdfs/about_us/Policy%20on%20RPT%20and%20its%20Materiality.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
The Company is debt free



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 2,14,657.60 8,44,009.90
Other income 30,787.60 77,202.30
Total income 2,45,445.20 9,21,212.20
2 Expenses
(a) Cost of materials consumed 72,092.00 2,77,557.50
(b) Purchases of stock-in-trade 11,350.10 40,879.50
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (92.90) (10,541.50)
(d) Employee benefit expense 46,134.50 1,79,041.00
(e) Finance costs 1,791.20 7,874.50
(f) Depreciation, depletion and amortisation expense 6,013.30 23,588.90
(f) Other Expenses
1 Other Expenses 82,020.80 2,49,333.60
Total other expenses 82,020.80 2,49,333.60
Total expenses 2,19,309.00 7,67,733.50
3 Total profit before exceptional items and tax 26,136.20 1,53,478.70
4 Exceptional items (36,875.90) (1,80,085.80)
5 Total profit before tax (10,739.70) (26,607.10)
6 Tax expense
7 Current tax 0.00 0.00
8 Deferred tax (3,349.50) (6,527.20)
9 Total tax expenses (3,349.50) (6,527.20)
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations (7,390.20) (20,079.90)
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period (7,390.20) (20,079.90)
17 Other comprehensive income net of taxes (374.60) (1,695.60)
18 Total Comprehensive Income for the period (7,764.80) (21,775.50)
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 2,822.00 2,822.00
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve 24,12,210.40
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations -2.62 -7.12
Diluted earnings (loss) per share from continuing operations -2.62 -7.11
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations -2.62 -7.12
Diluted earnings (loss) per share from continuing and discontinued operations -2.62 -7.11
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 1,74,765.80
Capital work-in-progress 6,736.20
Investment property 10,098.90
Goodwill 0.00
Other intangible assets 17,925.30
Intangible assets under development 9,195.90
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 15,20,221.00
Trade receivables, non-current 0.00
Loans, non-current 5,58,207.40
Other non-current financial assets
1 Other Non Current financial assets 3,674.10
Total of other non-current financial assets 3,674.10
Total non-current financial assets 20,82,102.50
Deferred tax assets (net) 604.00
Other non-current assets
1 Income tax assets (net) 20,165.10
2 Other non-current assets 17,414.50
Total of other non-current assets 37,579.60
Total non-current assets 23,39,008.20
2 Current assets
Inventories 1,28,806.40
Current financial asset
Current investments 0.00
Trade receivables, current 3,30,558.50
Cash and cash equivalents 29,183.10
Bank balance other than cash and cash equivalents 136.20
Loans, current 0.00
Other current financial assets
Total of other current financial assets 42,563.40
Total current financial assets 4,02,441.20
Current tax assets (net) 0.00
Other current assets
1 Other current assets 78,262.00
Total of other current assets 78,262.00
Total current assets 6,09,509.60
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 29,48,517.80
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 2,822.00
Other equity 24,12,210.40
Total equity attributable to owners of parent 24,15,032.40
Non controlling interest
Total equity 24,15,032.40
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease liabilities 7,474.20
2 Other financial liabilities 53,531.10
Total of other non-current financial liabilities 61,005.30
Total non-current financial liabilities 61,005.30
Provisions, non-current 0.00
Deferred tax liabilities (net) 17,661.40
Deferred government grants, Non-current 0.00
Other non-current liabilities
1 Other non-current liabilities 87,916.00
Total of other non-current liabilities 87,916.00
Total non-current liabilities 1,66,582.70
Current liabilities
Current financial liabilities
Borrowings, current 0.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 2,132.30
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 2,72,471.90
Total Trade payable 2,74,604.20
Other current financial liabilities
1 Other financial liabilities 42,159.00
2 Lease Liability 3,227.10
Total of other current financial liabilities 45,386.10
Total current financial liabilities 3,19,990.30
Other current liabilities 10,286.80
1 Other current financial liabilities 10,286.80
Total of other current liabilities 10,286.80
Provisions, current 36,625.60
Current tax liabilities (Net)
Deferred government grants, Current
Total current liabilities 3,66,902.70
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 5,33,485.40
Total equity and liabilites 29,48,517.80
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit or loss (105.10) (1,598.50)
Total Amount of items that will not be reclassified to profit and loss (105.10) (1,598.50)
2 Income tax relating to items that will not be reclassified to profit or loss 269.50 97.10
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income (374.60) (1,695.60)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax (26,607.10)
Adjustments for reconcile profit (loss)
Adjustments for finance costs 7,874.50
Adjustments for decrease (increase) in inventories (28,746.00)
Adjustments for decrease (increase) in trade receivables, current (1,12,560.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (68,199.30)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 1,43,885.60
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 23,588.90
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 0.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (39,989.70)
Adjustments for dividend income 0.70
Adjustments for interest income 17,507.50
Adjustments for share-based payments 446.60
Adjustments for fair value losses (gains) (2.50)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 161.40
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 1,80,085.80
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 89,037.10
Net cash flows from (used in) operations 62,430.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 8,099.60
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 54,330.40
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships (11.20)
Proceeds from sales of property, plant and equipment (27,703.30)
Purchase of property, plant and equipment 0.00
Proceeds from sales of investment property 0.00
Purchase of investment property 5.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 24.00
Cash advances and loans made to other parties (67,783.90)
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 4.80
Dividends received 0.70
Interest received 16,779.80
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 74.90
Net cash flows from (used in) investing activities 56,923.00
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries (69,989.80)
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 75.90
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 0.00
Payments of lease liabilities 4,352.40
Dividends paid 14,103.00
Interest paid 6,844.10
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (95,213.40)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 16,040.00
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents (2.00)
Net increase (decrease) in cash and cash equivalents 16,038.00
Cash and cash equivalents cash flow statement at beginning of period 13,145.10
Cash and cash equivalents cash flow statement at end of period 29,183.10





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Walker Chandiok & Co LLP Yes 31-05-2028


Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals SK SRO, Slovak Republic Wholly owned subsidiary Any other transaction Reimbursement Charges Paid - 0.70 0.00 0.00
2 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals SK SRO, Slovak Republic Wholly owned subsidiary Sale of goods or services - 188.20 0.00 0.00
3 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals SK SRO, Slovak Republic Wholly owned subsidiary Any other transaction Reimbursement Charges Received - 39.90 0.00 0.00
4 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals SP Zoo, Poland Wholly owned subsidiary Any other transaction Reimbursement Charges Paid - 4.70 0.00 0.00
5 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals SP Zoo, Poland Wholly owned subsidiary Sale of goods or services - 197.00 0.00 0.00
6 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals s.r.o. Wholly owned subsidiary Purchase of goods or services - 118.70 0.00 0.00
7 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals SP Zoo, Poland Wholly owned subsidiary Any other transaction Reimbursement Charges Received - 1.80 0.00 0.00
8 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals Europe Ltd, UK Wholly owned subsidiary Any other transaction Reimbursement Charges Received - 0.70 0.00 0.00
9 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Farmaceutica S.L.U. Wholly owned subsidiary Any other transaction Reimbursement Charges Received - 1.90 0.00 0.00
10 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Arzneimittel GmbH, Germany Wholly owned subsidiary Any other transaction Reimbursement Charges Received - 1.20 0.00 0.00
11 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharma Nordic (SE) Wholly owned subsidiary Any other transaction Reimbursement Charges Received - 1.60 0.00 0.00
12 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals s.r.o. Wholly owned subsidiary Any other transaction Reimbursement Charges Received - 67.10 0.00 0.00
13 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals s.r.o. Wholly owned subsidiary Sale of goods or services - 6,842.30 0.00 0.00
14 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals s.r.o. Wholly owned subsidiary Any other transaction Reimbursement Charges Paid - 58.00 0.00 0.00
15 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals s.r.o. Wholly owned subsidiary Purchase of goods or services - 16,339.30 0.00 0.00
16 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals s.r.o. Wholly owned subsidiary Purchase of fixed assets - 24.40 0.00 0.00
17 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SK SRO Wholly owned subsidiary Purchase of goods or services - 1,560.30 0.00 0.00
18 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SK SRO Wholly owned subsidiary Sale of goods or services - 4,603.50 0.00 0.00
19 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SK SRO Wholly owned subsidiary Sale of goods or services - 114.60 0.00 0.00
20 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SK SRO Wholly owned subsidiary Any other transaction Reimbursement Charges Received - 203.80 0.00 0.00
21 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SP Zoo Wholly owned subsidiary Purchase of goods or services - 2,273.70 0.00 0.00
22 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SP Zoo Wholly owned subsidiary Any other transaction Reimbursement Charges Received - 7.70 0.00 0.00
23 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SP Zoo Wholly owned subsidiary Sale of goods or services - 3,252.50 0.00 0.00
24 Glenmark Pharmaceuticals SP Zoo, Poland Glenmark Pharmaceuticals SK SRO Wholly owned subsidiary Any other transaction Reimbursement Charges Paid - 3.00 0.00 0.00
25 Glenmark Pharmaceuticals Europe Ltd, UK Glenmark Pharmaceuticals SP Zoo, Poland Wholly owned subsidiary Any other transaction Reimbursement Charges Paid - 5.00 0.00 0.00
26 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SP Zoo, Poland Wholly owned subsidiary Sale of goods or services - 13.40 0.00 0.00
27 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Europe Ltd. Wholly owned subsidiary Purchase of goods or services - 962.60 0.00 0.00
28 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Europe Ltd. Wholly owned subsidiary Any other transaction Reimbursement Charges Paid - 790.50 0.00 0.00
29 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Europe Ltd. Wholly owned subsidiary Sale of goods or services - 8,964.70 0.00 0.00
30 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Europe Ltd. Wholly owned subsidiary Sale of goods or services - 480.50 0.00 0.00
31 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Europe Ltd. Wholly owned subsidiary Any other transaction Reimbursement Charges Received - 566.40 0.00 0.00
32 Glenmark Pharmaceuticals s.r.o. Glenmark Farmaceutica S.L.U. Wholly owned subsidiary Sale of goods or services - 3,733.90 0.00 0.00
33 Glenmark Pharmaceuticals s.r.o. Sintesy Pharma S.r.l. Wholly owned subsidiary Sale of goods or services - 83.20 0.00 0.00
34 Glenmark Pharmaceuticals s.r.o. Glenmark Farmaceutica S.L.U. Wholly owned subsidiary Sale of goods or services - 11.50 0.00 0.00
35 Glenmark Pharmaceuticals s.r.o. Glenmark Farmaceutica S.L.U. Wholly owned subsidiary Any other transaction Reimbursement Charges Received - 94.00 0.00 0.00
36 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals BV Wholly owned subsidiary Purchase of goods or services - 76.40 0.00 0.00
37 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals BV Wholly owned subsidiary Sale of goods or services - 9,922.50 0.00 0.00
38 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals BV Wholly owned subsidiary Sale of goods or services - 4.40 0.00 0.00
39 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals BV Wholly owned subsidiary Any other transaction Reimbursement Charges Received - 85.20 0.00 0.00
40 Glenmark Pharmaceuticals s.r.o. Glenmark Pharma Nordic Wholly owned subsidiary Sale of goods or services - 6,000.10 0.00 0.00
41 Glenmark Pharmaceuticals s.r.o. Glenmark Pharma Nordic Wholly owned subsidiary Sale of goods or services - 7.90 0.00 0.00
42 Glenmark Pharmaceuticals s.r.o. Glenmark Pharma Nordic Wholly owned subsidiary Any other transaction Reimbursement Charges Paid - 103.60 0.00 0.00
43 Glenmark Pharmaceuticals s.r.o. Glenmark Pharma Nordic Wholly owned subsidiary Any other transaction Reimbursement Charges Received - 177.80 0.00 0.00
44 Glenmark Pharmaceuticals s.r.o. Sintesy Pharma S.r.l. Wholly owned subsidiary Sale of goods or services - 2,524.60 0.00 0.00
45 Glenmark Pharmaceuticals s.r.o. Sintesy Pharma S.r.l. Wholly owned subsidiary Any other transaction Reimbursement Charges Received - 16.40 0.00 0.00
46 Glenmark Pharmaceuticals s.r.o. Sintesy Pharma S.r.l. Wholly owned subsidiary Purchase of fixed assets - 59.80 0.00 0.00
47 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH, Germany Wholly owned subsidiary Purchase of fixed assets - 622.60 0.00 0.00
48 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH, Germany Wholly owned subsidiary Purchase of goods or services - 1,571.40 0.00 0.00
49 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH, Germany Wholly owned subsidiary Sale of goods or services - 21,620.30 0.00 0.00
50 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH, Germany Wholly owned subsidiary Sale of goods or services - 5.50 0.00 0.00
51 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH, Germany Wholly owned subsidiary Sale of goods or services - 201.10 0.00 0.00
52 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH, Germany Wholly owned subsidiary Sale of goods or services - 13.80 0.00 0.00
53 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH, Germany Wholly owned subsidiary Any other transaction Reimbursement Charges Received - 5.20 0.00 0.00
54 Glenmark Pharmaceuticals s.r.o. Glenmark Farmaceuticals Ltda Brazil Wholly owned subsidiary Any other transaction Reimbursement Charges Paid - 38.50 0.00 0.00
55 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH, Germany Wholly owned subsidiary Any other transaction Reimbursement Charges Received - 128.90 0.00 0.00
56 Glenmark Pharmaceuticals s.r.o. Sintesy Pharma S.r.l. Wholly owned subsidiary Any other transaction Compensation payment in accordance with agreement - 40.80 0.00 0.00
57 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH (Austria) Wholly owned subsidiary Any other transaction Compensation payment in accordance with agreement - 973.10 0.00 0.00
58 Glenmark Pharmaceuticals s.r.o. Glenmark Pharma Nordic (SE) Wholly owned subsidiary Any other transaction Compensation payment in accordance with agreement - 4,997.40 0.00 0.00
59 Glenmark Pharmaceuticals s.r.o. GLENMARK UKRAINE, LLC Wholly owned subsidiary Any other transaction Reimbursement Charges Received - 0.90 0.00 0.00
60 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SK SRO, Slovak Republic Wholly owned subsidiary Any other transaction Reimbursement Charges Paid - 1.30 0.00 0.00
61 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SP Zoo, Poland Wholly owned subsidiary Any other transaction Reimbursement Charges Paid - 3.00 0.00 0.00
62 Glenmark Pharmaceuticals s.r.o. Sintesy Pharma S.r.l. Wholly owned subsidiary Any other transaction Reimbursement Charges Paid - 15.10 0.00 0.00
63 Glenmark Pharmaceuticals Europe Ltd. Glenmark Arzneimittel GmbH, Germany Wholly owned subsidiary Purchase of goods or services - 147.80 0.00 0.00
64 Glenmark Pharmaceuticals Europe Ltd. Sintesy Pharma S.r.l. Wholly owned subsidiary Any other transaction Reimbursement Charges Paid - 92.30 0.00 0.00
65 Glenmark Arzneimittel GmbH - Germany Glenmark Arzneimittel GmbH (Austria) Wholly owned subsidiary Purchase of goods or services - 200.50 0.00 0.00
66 Glenmark Pharmaceuticals Europe Ltd. Glenmark Arzneimittel GmbH (Austria) Wholly owned subsidiary Any other transaction Reimbursement Charges Received - 2.50 0.00 0.00
67 Glenmark Pharmaceuticals Europe Ltd. Glenmark Arzneimittel GmbH, Germany Wholly owned subsidiary Any other transaction Reimbursement Charges Received - 65.20 0.00 0.00
68 Glenmark Pharmaceuticals Europe Ltd. Glenmark Pharmaceuticals BV Wholly owned subsidiary Purchase of goods or services - 324.60 0.00 0.00
69 Glenmark Pharmaceuticals Europe Ltd. Glenmark Pharmaceuticals BV Wholly owned subsidiary Any other transaction Reimbursement Charges Received - 17.80 0.00 0.00
70 Glenmark Pharmaceuticals Europe Ltd. Glenmark Farmaceutica S.L.U. Wholly owned subsidiary Any other transaction Reimbursement Charges Received - 17.90 0.00 0.00
71 Glenmark Pharmaceuticals Europe Ltd. Glenmark Farmaceuticals Ltda Brazil Wholly owned subsidiary Any other transaction Reimbursement Charges Received - 2.90 0.00 0.00
72 Glenmark Pharmaceuticals Europe Ltd. Glenmark Pharma Nordic (SE) Wholly owned subsidiary Any other transaction Reimbursement Charges Received - 12.20 0.00 0.00
73 Glenmark Pharmaceuticals Europe Ltd. Sintesy Pharma S.r.l. Wholly owned subsidiary Interest paid - 39.70 0.00 0.00
74 Glenmark Pharmaceuticals Europe Ltd. Glenmark Arzneimittel GmbH, Germany Wholly owned subsidiary Interest paid - 555.70 0.00 0.00
75 Glenmark Pharmaceuticals Mexico SA de CV Glenmark Generics S.A. Wholly owned subsidiary Purchase of goods or services - 340.30 0.00 0.00
76 Glenmark Pharmaceuticals Mexico SA de CV Glenmark Farmaceuticals Ltda Brazil Wholly owned subsidiary Purchase of goods or services - 47.10 0.00 0.00
77 Glenmark Pharmaceuticals Ltd. -Peru Glenmark Farmaceutica SpA Wholly owned subsidiary Any other transaction Reimbursement Charges Received - 24.60 0.00 0.00
78 Glenmark Farmaceuticals Ltda Brazil Glenmark Pharmaceuticals Ltd. -Peru Wholly owned subsidiary Sale of goods or services - 0.40 0.00 0.00
79 Glenmark Farmaceuticals Ltda Brazil Glenmark Pharmaceuticals Ecaudor S.A Wholly owned subsidiary Sale of goods or services - 9.10 0.00 0.00
80 Glenmark Farmaceuticals Ltda Brazil Glenmark Generics S.A. Wholly owned subsidiary Purchase of goods or services - 277.50 0.00 0.00
81 Glenmark Pharmaceuticals Ecaudor S.A Glenmark Generics S.A. Wholly owned subsidiary Purchase of goods or services - 5.90 0.00 0.00
82 Glenmark Pharmaceuticals Colombia SAS Glenmark Generics S.A. Wholly owned subsidiary Purchase of goods or services - 30.60 0.00 0.00
83 Glenmark Pharmaceuticals Europe Ltd. Glenmark Pharmaceuticals BV Wholly owned subsidiary Any other transaction Reimbursement charges paid - 16.40 0.00 0.00
84 Glenmark Pharmaceuticals Europe Ltd. Glenmark Impex LLC Wholly owned subsidiary Any other transaction Reimbursement charges paid - 2.00 0.00 0.00
85 Glenmark Pharmaceuticals Europe Ltd. Glenmark Farmaceutica S.L.U. Wholly owned subsidiary Any other transaction Reimbursement charges paid - 50.60 0.00 0.00
86 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals SK SRO, Slovak Republic Wholly owned subsidiary Any other transaction Payable - 0.00 0.50 0.70
87 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals SK SRO, Slovak Republic Wholly owned subsidiary Any other transaction Receivable - 0.00 284.90 1.60
88 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals SP Zoo, Poland Wholly owned subsidiary Any other transaction Payable - 0.00 0.80 3.90
89 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals SP Zoo, Poland Wholly owned subsidiary Any other transaction Receivable - 0.00 68.10 15.90
90 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Ukraine LLC Wholly owned subsidiary Any other transaction Receivable - 0.00 0.20 0.20
91 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals s.r.o. Wholly owned subsidiary Any other transaction Payable - 0.00 2,211.10 812.00
92 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharma Nordic (SE) Wholly owned subsidiary Any other transaction Receivable - 0.00 0.00 1.70
93 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals s.r.o. Wholly owned subsidiary Any other transaction Receivable - 0.00 6,529.60 3,933.00
94 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SK SRO, Slovak Republic Wholly owned subsidiary Any other transaction Payable - 0.00 952.10 618.80
95 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SK SRO, Slovak Republic Wholly owned subsidiary Any other transaction Receivable - 0.00 4,730.50 4,846.90
96 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SP Zoo, Poland Wholly owned subsidiary Any other transaction Payable - 0.00 1,615.10 1,345.20
97 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SP Zoo, Poland Wholly owned subsidiary Any other transaction Receivable - 0.00 7,418.70 5,939.80
98 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Europe Ltd, UK Wholly owned subsidiary Any other transaction Payable - 0.00 3,093.90 483.90
99 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Europe Ltd, UK Wholly owned subsidiary Any other transaction Receivable - 0.00 2,658.00 (685.90)
100 Glenmark Pharmaceuticals s.r.o. Glenmark Farmaceutica S.L.U. Wholly owned subsidiary Any other transaction Receivable - 0.00 4,433.10 4,125.20
101 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals BV Wholly owned subsidiary Any other transaction Payable - 0.00 84.40 39.40
102 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals BV Wholly owned subsidiary Any other transaction Receivable - 0.00 329.60 4,334.80
103 Glenmark Pharmaceuticals s.r.o. Glenmark Pharma Nordic (SE) Wholly owned subsidiary Any other transaction Receivable - 0.00 12,149.80 15,221.10
104 Glenmark Pharmaceuticals s.r.o. Glenmark Pharma Nordic (SE) Wholly owned subsidiary Any other transaction Payable - 0.00 0.00 5,251.90
105 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH, Germany Wholly owned subsidiary Any other transaction Payable - 0.00 1,644.80 142.10
106 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH, Germany Wholly owned subsidiary Any other transaction Receivable - 0.00 2,692.10 8,209.20
107 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH (Austria) Wholly owned subsidiary Any other transaction Receivable - 0.00 190.20 430.00
108 Glenmark Pharmaceuticals s.r.o. Glenmark Generics S.A. Wholly owned subsidiary Any other transaction Receivable - 0.00 25.90 26.80
109 Glenmark Pharmaceuticals s.r.o. Sintesy Pharma S.r.l. Wholly owned subsidiary Any other transaction Receivable - 0.00 1,746.30 3,420.10
110 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH (Austria) Wholly owned subsidiary Any other transaction Payable - 0.00 0.00 1,022.60
111 Glenmark Pharmaceuticals s.r.o. Glenmark Farmaceuticals Ltda Brazil Wholly owned subsidiary Any other transaction Payable - 0.00 14.70 22.80
112 Glenmark Pharmaceuticals s.r.o. Sintesy Pharma S.r.l. Wholly owned subsidiary Any other transaction Payable - 0.00 0.00 114.40
113 Glenmark Pharmaceuticals s.r.o. Glenmark Ukraine LLC Wholly owned subsidiary Any other transaction Receivable - 0.00 0.00 1.00
114 Glenmark Pharmaceuticals SP Zoo, Poland Glenmark Pharmaceuticals SK SRO, Slovak Republic Wholly owned subsidiary Any other transaction Receivable - 0.00 0.00 3.10
115 Glenmark Pharmaceuticals Europe Limited Glenmark Farmaceutica S.L.U. Wholly owned subsidiary Any other transaction Receivable - 0.00 35.30 37.10
116 Glenmark Pharmaceuticals Europe Limited Glenmark Farmaceutica S.L.U. Wholly owned subsidiary Any other transaction Payable - 0.00 0.20 0.00
117 Glenmark Pharmaceuticals Europe Limited Glenmark Pharmaceuticals BV Wholly owned subsidiary Any other transaction Payable - 0.00 744.40 141.70
118 Glenmark Pharmaceuticals Europe Limited Glenmark Pharmaceuticals BV Wholly owned subsidiary Any other transaction Receivable - 0.00 89.30 104.70
119 Glenmark Pharmaceuticals Europe Limited Glenmark Pharmaceuticals SP Zoo, Poland Wholly owned subsidiary Any other transaction Payable - 0.00 5.10 5.20
120 Glenmark Pharmaceuticals Europe Limited Glenmark Pharma Nordic (SE) Wholly owned subsidiary Any other transaction Receivable - 0.00 5.80 22.80
121 Glenmark Pharmaceuticals Europe Limited Glenmark Impex LLC Wholly owned subsidiary Any other transaction Receivable - 0.00 5.40 5.70
122 Glenmark Pharmaceuticals Europe Limited Sintesy Pharma S.r.l. Wholly owned subsidiary Any other transaction Receivable - 0.00 100.40 196.30
123 Glenmark Pharmaceuticals Europe Limited Glenmark Arzneimittel GmbH, Germany Wholly owned subsidiary Any other transaction Payable - 0.00 115.20 17.40
124 Glenmark Pharmaceuticals Europe Limited Glenmark Arzneimittel GmbH, Germany Wholly owned subsidiary Any other transaction Receivable - 0.00 175.10 36.90
125 Glenmark Pharmaceuticals Europe Limited Glenmark Generics S.A. Wholly owned subsidiary Any other transaction Receivable - 0.00 5.50 6.50
126 Glenmark Pharmaceuticals Europe Limited Glenmark Pharmaceuticals Mexico SA de CV Wholly owned subsidiary Any other transaction Receivable - 0.00 2.70 2.80
127 Glenmark Pharmaceuticals Europe Limited Glenmark Farmaceuticals Ltda Brazil Wholly owned subsidiary Any other transaction Receivable - 0.00 41.60 46.20
128 Glenmark Pharmaceuticals Europe Limited Sintesy Pharma S.r.l. Wholly owned subsidiary Any other transaction Loan given - 0.00 1,325.40 1,434.50
129 Glenmark Pharmaceuticals Europe Limited Glenmark Arzneimittel GmbH, Germany Wholly owned subsidiary Any other transaction Loan Payable - 0.00 32,456.50 32,420.70
130 Glenmark Pharmaceuticals Europe Limited Glenmark Arzneimittel GmbH (Austria) Wholly owned subsidiary Any other transaction Receivable - 0.00 6.20 6.10
131 Glenmark Arzneimittel GmbH, Germany Glenmark Arzneimittel GmbH (Austria) Wholly owned subsidiary Any other transaction Receivable - 0.00 271.40 211.30
132 Glenmark Arzneimittel GmbH, Germany Sintesy Pharma S.r.l. Wholly owned subsidiary Any other transaction Receivable - 0.00 0.00 82.70
133 Glenmark Pharmaceuticals Kenya Limited Glenmark Pharmaceuticals South Africa (Pty) Ltd Wholly owned subsidiary Any other transaction Payable - 0.00 12.90 12.90
134 Glenmark Pharmaceuticals Kenya Limited Glenmark Generics S.A. Wholly owned subsidiary Any other transaction Payable - 0.00 32.70 0.00
135 Glenmark Pharmaceuticals Kenya Limited Glenmark Pharmaceuticals Egypt S.A.E Wholly owned subsidiary Any other transaction Receivable - 0.00 19.40 20.70
136 Glenmark Pharmaceuticals South Africa (Pty) Ltd Glenmark South Africa (Pty) Ltd Wholly owned subsidiary Any other transaction Loan given - 0.00 4,857.30 5,197.50
137 Glenmark Pharmaceuticals South Africa (Pty) Ltd Glenmark South Africa (Pty) Ltd Wholly owned subsidiary Any other transaction Investment - 0.00 259.00 259.00
138 Glenmark Pharmaceuticals Mexico SA de CV Glenmark Generics S.A. Wholly owned subsidiary Any other transaction Payable - 0.00 61.10 0.00
139 Glenmark Farmaceuticals Ltda Brazil Glenmark Pharmaceuticals Mexico SA de CV Wholly owned subsidiary Any other transaction Receivable - 0.00 754.70 852.50
140 Glenmark Farmaceuticals Ltda Brazil Glenmark Pharmaceuticals Ltd. Peru Wholly owned subsidiary Any other transaction Payable - 0.00 3.80 89.10
141 Glenmark Farmaceuticals Ltda Brazil Glenmark Generics S.A. Wholly owned subsidiary Any other transaction Receivable - 0.00 116.10 0.00
142 Glenmark Farmaceuticals Ltda Brazil Glenmark Pharmaceuticals Ecaudor S.A Wholly owned subsidiary Any other transaction Receivable - 0.00 3.50 13.70
143 Glenmark Farmaceuticals Ltda Brazil Glenmark Generics S.A. Wholly owned subsidiary Any other transaction Payable - 0.00 270.80 0.00
144 Glenmark Generics S.A. Glenmark Pharmaceuticals Colombia Wholly owned subsidiary Any other transaction Receivable - 0.00 0.00 26.40
145 Glenmark Pharmaceuticals Ltd. -Peru Glenmark Farmaceutica SpA Wholly owned subsidiary Any other transaction Loan - 0.00 0.00 26.00
146 Glenmark Generics S.A. Glenmark Pharmaceuticals Venezuela Wholly owned subsidiary Any other transaction Receivable - 0.00 158.40 164.40
147 Glenmark Holding S.A. GLENMARK THERAPEUTICS INC Wholly owned subsidiary Investment - 0.00 24,817.00 24,817.00
148 Glenmark Holding S.A. GLEN MARK FARMACEUTICA LTDA Wholly owned subsidiary Investment - 17,666.00 1,56,705.20 1,74,371.20
149 Glenmark Holding S.A. GLEN MARK PHARMACEUTICALS S.r.o Wholly owned subsidiary Investment - 0.00 71,947.80 71,947.80
150 Glenmark Holding S.A. GLENAMRK PHARMACEUTICALS SP Z.O.O Wholly owned subsidiary Investment - 0.00 3,678.30 3,678.30
151 Glenmark Holding S.A. Glenmark Specialty SA Wholly owned subsidiary Investment - 0.00 1,51,866.90 1,51,866.90
152 Glenmark Holding S.A. Glenmark Farmaceutica S.L.U. Wholly owned subsidiary Investment - 0.00 2.10 2.10
153 Glenmark Holding S.A. GLEN MARK PHARMACEUTICALS INC. Wholly owned subsidiary Investment - 0.00 3,83,635.40 3,83,635.40
154 Glenmark Holding S.A. Glenmark Pharmaceuticals Canada Inc Wholly owned subsidiary Investment - 0.00 1,075.70 1,075.70
155 Glenmark Holding S.A. GLENMARK GENERICS S.A. Wholly owned subsidiary Investment - 11,642.80 1,05,537.10 1,17,179.90
156 Glenmark Holding S.A. Glenmark Arzneimittel GmBH, Germany Wholly owned subsidiary Investment - 0.00 1,068.40 1,068.40
157 Glenmark Holding S.A. Glenmark Pharmaceuticals BV Wholly owned subsidiary Investment - 0.00 14.80 14.80
158 Glenmark Holding S.A. Glenmark Pharmaceuticals Distribution, Czech Wholly owned subsidiary Investment - 0.00 16,461.20 16,461.20
159 Glenmark Holding S.A. Glenmark Pharmaceuticals AB Wholly owned subsidiary Investment - 0.00 1,739.30 1,739.30
160 Glenmark Holding S.A. Glenmark Ukraine LLC Wholly owned subsidiary Investment - 0.00 461.50 461.50
161 Glenmark Holding S.A. Ichnos Glenmark Innovation Inc. Wholly owned subsidiary Investment - 3,268.20 4,08,886.90 4,12,155.10
162 Glenmark Holding S.A. Sintesy Pharma S.R.L. Wholly owned subsidiary Investment - 0.00 1,559.50 1,559.50
163 Glenmark Holding S.A. Glenmark Farmaceutica Spa., Chile Wholly owned subsidiary Investment - 88.30 124.20 212.50
164 Glenmark Holding S.A. Glenmark Arzneimittel GmBH, Austria Wholly owned subsidiary Investment - 0.00 522.50 522.50
165 Glenmark Specialty S.A. Glenmark Pharmaceuticals Europe Ltd. Wholly owned subsidiary Any other transaction Payable - 0.00 666.30 2,181.00
166 Glenmark Specialty S.A. Glenmark Pharmaceuticals Europe Ltd. Wholly owned subsidiary Any other transaction Expense - 1,406.40 0.00 0.00
167 Glenmark Specialty S.A. Glenmark Pharmaceuticals Inc. USA Wholly owned subsidiary Any other transaction Payable - 0.00 2,402.00 3,102.90
168 Glenmark Specialty S.A. Glenmark Pharmaceuticals Inc. USA Wholly owned subsidiary Any other transaction Expense - 1,454.20 0.00 0.00
169 Glenmark Specialty S.A. GLENMARK FARMAC�UTICA LTDA Wholly owned subsidiary Any other transaction Payable - 0.00 0.50 0.00
170 Glenmark Specialty S.A. Glenmark Pharmaceuticals S.R.O. Wholly owned subsidiary Any other transaction Payable - 0.00 287.40 307.40
171 Glenmark Specialty S.A. Glenmark Pharmaceuticals S.R.O. Wholly owned subsidiary Any other transaction Expense - 305.50 0.00 0.00
172 Glenmark Specialty S.A. Glenmark Pharmaceuticals Australia Wholly owned subsidiary Any other transaction Expense - 134.20 0.00 0.00
173 Glenmark Specialty S.A. Glenmark Arzneimittel GmBH, Germany Wholly owned subsidiary Any other transaction Expense - 237.60 0.00 0.00
174 Glenmark Specialty S.A. Glenmark Arzneimittel GmBH, Germany Wholly owned subsidiary Any other transaction Payable - 0.00 0.00 253.00
175 Glenmark Specialty S.A. Glenmark Pharmaceuticals FZE Wholly owned subsidiary Any other transaction Expense - 627.70 0.00 0.00
176 Glenmark Specialty S.A. Glenmark Pharmaceuticals FZE Wholly owned subsidiary Any other transaction Payable - 0.00 0.00 668.30
177 Glenmark Specialty S.A. Glenmark Pharmaceuticals Canada Inc Wholly owned subsidiary Any other transaction Expense - 4.60 0.00 0.00
178 Glenmark Specialty S.A. Glenmark Pharmaceuticals Canada Inc Wholly owned subsidiary Any other transaction Payable - 0.00 0.00 4.90
179 Glenmark Specialty S.A. Glenmark Pharmaceuticals S.R.O. Wholly owned subsidiary Any other transaction Receivable - 0.00 27,532.20 32,067.60
180 Glenmark Specialty S.A. Glenmark Pharmaceuticals S.R.O. Wholly owned subsidiary Sale of goods or services - 15,432.20 0.00 0.00
181 Glenmark Specialty S.A. GLENMARK PHARMACEUTICALS KENYA LTD. Wholly owned subsidiary Any other transaction Receivable - 0.00 0.00 104.50
182 Glenmark Specialty S.A. GLENMARK PHARMACEUTICALS KENYA LTD. Wholly owned subsidiary Sale of goods or services - 97.50 0.00 0.00
183 Glenmark Specialty S.A. Glenmark Pharmaceuticals Malaysia Sdn Bhd Wholly owned subsidiary Any other transaction Receivable - 0.00 271.00 373.50
184 Glenmark Specialty S.A. Glenmark Pharmaceuticals Malaysia Sdn Bhd Wholly owned subsidiary Sale of goods or services - 606.70 0.00 0.00
185 Glenmark Specialty S.A. Glenmark Pharmaceuticals Peru S.A Wholly owned subsidiary Any other transaction Receivable - 0.00 531.20 581.60
186 Glenmark Specialty S.A. Glenmark Pharmaceuticals Peru S.A Wholly owned subsidiary Sale of goods or services - 103.30 0.00 0.00
187 Glenmark Specialty S.A. GLENMARK PHARMACEUTICALS ECUADOR S. Wholly owned subsidiary Any other transaction Receivable - 0.00 0.00 113.90
188 Glenmark Specialty S.A. GLENMARK PHARMACEUTICALS ECUADOR S. Wholly owned subsidiary Sale of goods or services - 106.90 0.00 0.00
189 Glenmark Specialty S.A. Glenmark Impex LLC Wholly owned subsidiary Any other transaction Receivable - 0.00 8,456.60 10,678.80
190 Glenmark Specialty S.A. Glenmark Impex LLC Wholly owned subsidiary Sale of goods or services - 1,596.70 0.00 0.00
191 Glenmark Specialty S.A. Glenmark Pharmaceuticals Inc. USA Wholly owned subsidiary Any other transaction Receivable - 0.00 60,872.40 56,179.20
192 Glenmark Specialty S.A. Glenmark Pharmaceuticals Inc. USA Wholly owned subsidiary Sale of goods or services - 5,445.20 0.00 0.00
193 Glenmark Specialty S.A. GLENMARK PHARMACEUTICALS MEXICO SA Wholly owned subsidiary Any other transaction Receivable - 0.00 3,172.20 5,217.70
194 Glenmark Specialty S.A. GLENMARK PHARMACEUTICALS MEXICO SA Wholly owned subsidiary Sale of goods or services - 1,721.30 0.00 0.00
195 Glenmark Specialty S.A. Glenmark Holding S.A. Wholly owned subsidiary Any other transaction Receivable - 0.00 13.40 142.30
196 Glenmark Specialty S.A. Glenmark Holding S.A. Wholly owned subsidiary Any other transaction Service income - 140.30 0.00 0.00
197 Glenmark Specialty S.A. Glenmark Pharmaceuticals FZE Wholly owned subsidiary Any other transaction Receivable - 0.00 341.30 447.40
198 Glenmark Specialty S.A. Glenmark Pharmaceuticals FZE Wholly owned subsidiary Sale of goods or services - 80.60 0.00 0.00
199 Glenmark Specialty S.A. Glenmark Pharmaceuticals South Africa (Pty) Ltd. Wholly owned subsidiary Any other transaction Receivable - 0.00 3,472.30 1,274.00
200 Glenmark Specialty S.A. Glenmark Pharmaceuticals South Africa (Pty) Ltd. Wholly owned subsidiary Sale of goods or services - 1,170.40 0.00 0.00
201 Glenmark Specialty S.A. Glenmark Pharmaceutical Colombia S. Wholly owned subsidiary Any other transaction Receivable - 0.00 0.00 426.50
202 Glenmark Specialty S.A. Glenmark Pharmaceutical Colombia S. Wholly owned subsidiary Sale of goods or services - 398.30 0.00 0.00
203 Glenmark Specialty S.A. GLENMARK PHILIPPINES INC Wholly owned subsidiary Any other transaction Receivable - 0.00 0.00 7.40
204 Glenmark Specialty S.A. GLENMARK PHILIPPINES INC Wholly owned subsidiary Sale of goods or services - 6.70 0.00 0.00
205 Glenmark Specialty S.A. GLENMARK PHARMACEUTICALS (THAILAND) Wholly owned subsidiary Any other transaction Receivable - 0.00 0.00 261.60
206 Glenmark Specialty S.A. GLENMARK PHARMACEUTICALS (THAILAND) Wholly owned subsidiary Sale of goods or services - 246.90 0.00 0.00
207 Glenmark Specialty S.A. Glenmark Pharmaceuticals Australia Wholly owned subsidiary Any other transaction Receivable - 0.00 956.50 851.30
208 Glenmark Specialty S.A. Glenmark Pharmaceuticals Australia Wholly owned subsidiary Interest received - 53.00 0.00 0.00
209 Glenmark Specialty S.A. IGI Therapeutics SA Wholly owned subsidiary Any other transaction Receivable - 0.00 0.00 37.30
210 Glenmark Specialty S.A. IGI Therapeutics SA Wholly owned subsidiary Any other transaction Other income - 35.00 0.00 0.00
211 Glenmark Holding S.A. Glenmark Specialty S.A. Wholly owned subsidiary Any other transaction Loan Receivable - 0.00 1,01,052.60 1,23,140.80 Loan 4.500 5 Years Unsecured Business Purpose
212 Glenmark Holding S.A. Glenmark Specialty S.A. Wholly owned subsidiary Interest received - 2,551.20 0.00 0.00
213 Glenmark Holding S.A. Glenmark Specialty S.A. Wholly owned subsidiary Any other transaction Loan Given - 20,470.00 0.00 0.00
214 Glenmark Holding S.A. Glenmark Pharmaceuticals Sp Z.o.o Wholly owned subsidiary Any other transaction Loan Receivable - 0.00 973.30 13.70 Loan 5.00 5 Years Unsecured Business Purpose
215 Glenmark Holding S.A. Glenmark Pharmaceuticals Sp Z.o.o Wholly owned subsidiary Interest received - 27.60 0.00 0.00
216 Glenmark Holding S.A. Glenmark Pharmaceuticals Inc. Wholly owned subsidiary Any other transaction Loan Receivable - 0.00 4,06,407.10 4,32,080.40 Loan 5.00 3 Years Unsecured Business Purpose
217 Glenmark Holding S.A. Glenmark Pharmaceuticals Inc. Wholly owned subsidiary Interest received - 10,830.70 0.00 0.00
218 Glenmark Holding S.A. Glenmark Pharmaceuticals Inc. Wholly owned subsidiary Any other transaction Loan Given - 90,891.30 0.00 0.00
219 Glenmark Holding S.A. GLENMARK PHARMACEUTICALS MEXICO SA Wholly owned subsidiary Any other transaction Loan Receivable - 0.00 3,066.60 1,829.70 Loan 5.00 5 Years Unsecured Business Purpose
220 Glenmark Holding S.A. GLENMARK PHARMACEUTICALS MEXICO SA Wholly owned subsidiary Interest received - 75.00 0.00 0.00
221 Glenmark Holding S.A. GLENMARK PHARMACEUTICALS KENYA LTD. Wholly owned subsidiary Any other transaction Loan Receivable - 0.00 2,665.70 214.00 Loan 5.00 3 Years Unsecured Business Purpose
222 Glenmark Holding S.A. GLENMARK PHARMACEUTICALS KENYA LTD. Wholly owned subsidiary Interest received - 52.70 0.00 0.00
223 Glenmark Holding S.A. Glenmark Pharmaceuticals Colombia Wholly owned subsidiary Any other transaction Loan Receivable - 0.00 1,777.20 1,876.60 Loan 5.00 5 Years Unsecured Business Purpose
224 Glenmark Holding S.A. Glenmark Pharmaceuticals Colombia Wholly owned subsidiary Interest received - 43.40 0.00 0.00
225 Glenmark Holding S.A. Glenmark Pharmaceuticals Peru S.A Wholly owned subsidiary Any other transaction Loan Receivable - 0.00 222.10 (0.10) Loan 5.00 3 Years Unsecured Business Purpose
226 Glenmark Holding S.A. Glenmark Pharmaceuticals Peru S.A Wholly owned subsidiary Interest received - 5.30 0.00 0.00
227 Glenmark Holding S.A. Glenmark Pharmaceuticals Ecuador Wholly owned subsidiary Any other transaction Loan Receivable - 0.00 1,777.20 1,876.60 Loan 5.00 3 Years Unsecured Business Purpose
228 Glenmark Holding S.A. Glenmark Pharmaceuticals Ecuador Wholly owned subsidiary Interest received - 43.40 0.00 0.00
229 Glenmark Holding S.A. Glenmark Farmac�utica Ltda Wholly owned subsidiary Any other transaction Interest Receivable - 0.00 45.70 48.40
230 Glenmark Holding S.A. Ichnos Glenmark Innovation Inc. Wholly owned subsidiary Any other transaction Dividend Receivable - 0.00 1,68,852.40 10,172.40
231 Glenmark Holding S.A. Ichnos Glenmark Innovation Inc. Wholly owned subsidiary Any other transaction Dividend Receivable - 20,249.40 0.00 0.00
232 Glenmark Holding S.A. Glenmark Pharmaceuticals Europe Ltd. Wholly owned subsidiary Any other transaction Loan Payable - 0.00 3,917.00 12,238.00 Loan 5.2100 1 Year Unsecured Business Purpose
233 Glenmark Holding S.A. Glenmark Pharmaceuticals Europe Ltd. Wholly owned subsidiary Interest paid - 100.50 0.00 0.00
234 Glenmark Holding S.A. Glenmark Pharmaceuticals Europe Ltd. Wholly owned subsidiary Any other transaction Loan Payable - 7,543.30 0.00 0.00
235 Glenmark Holding S.A. Glenmark Pharmaceuticals B.V. Wholly owned subsidiary Interest paid - 0.00 14,904.10 24,341.20 Loan 3.3200 1 Year Unsecured Business Purpose
236 Glenmark Holding S.A. Glenmark Pharmaceuticals B.V. Wholly owned subsidiary Interest paid - 249.40 0.00 0.00
237 Glenmark Holding S.A. Glenmark Pharmaceuticals B.V. Wholly owned subsidiary Any other transaction Loan Taken - 8,000.90 0.00 0.00
238 Glenmark Holding S.A. Glenmark Specialty S.A. Wholly owned subsidiary Any other transaction Expense payable - 0.00 13.40 142.30
239 Glenmark Holding S.A. Glenmark Specialty S.A. Wholly owned subsidiary Any other transaction Expense - 140.30 0.00 0.00
240 Glenmark Holding S.A. IGI Therapeutics SA Wholly owned subsidiary Any other transaction Loan Payable - 0.00 4,13,976.80 0.00 Loan 4.7500 0.5 Years Unsecured Business Purpose
241 Glenmark Holding S.A. IGI Therapeutics SA Wholly owned subsidiary Any other transaction Loan Payable - 0.00 0.00 14,074.70 Loan 4.00 1 Year Unsecured Business Purpose
242 Glenmark Holding S.A. IGI Therapeutics SA Wholly owned subsidiary Any other transaction Loan Payable - 0.00 1,73,107.60 1,57,431.20 Loan 4.00 3 Years Unsecured Business Purpose
243 Glenmark Holding S.A. IGI Therapeutics SA Wholly owned subsidiary Any other transaction Loan taken - 13,024.20 0.00 0.00
244 Glenmark Holding S.A. IGI Therapeutics SA Wholly owned subsidiary Interest paid - 5,798.20 0.00 0.00
245 Glenmark Holding S.A. Ichnos Glenmark Innovation Inc. Wholly owned subsidiary Any other transaction Loan Payable - 0.00 0.00 1,87,048.40 Loan 4.00 4.5 Years Unsecured Business Purpose
246 Glenmark Holding S.A. Ichnos Glenmark Innovation Inc. Wholly owned subsidiary Any other transaction Loan Taken - 1,81,261.10 0.00 0.00
247 Glenmark Holding S.A. Ichnos Glenmark Innovation Inc. Wholly owned subsidiary Interest paid - 2,775.80 0.00 0.00
248 Glenmark Holding S.A. Glenmark Arzeneimittel Germany Wholly owned subsidiary Any other transaction Loan Payable - 0.00 31,133.10 37,081.30
249 Glenmark Holding S.A. Glenmark Arzeneimittel Germany Wholly owned subsidiary Any other transaction Loan Taken - 4,036.30 0.00 0.00 Loan 3.3200 1 Year Unsecured Business Purpose
250 Glenmark Holding S.A. Glenmark Arzeneimittel Germany Wholly owned subsidiary Interest paid - 480.10 0.00 0.00
251 Glenmark Pharmaceuticals Limited Glenmark Farmaceutica Ltda. Wholly owned subsidiary Sale of goods or services - 7,103.90 0.00 0.00
252 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Australia) Wholly owned subsidiary Sale of goods or services - 529.20 0.00 0.00
253 Glenmark Pharmaceuticals Limited Glenmark Phillipines Inc., Philippines Wholly owned subsidiary Sale of goods or services - 1,258.50 0.00 0.00
254 Glenmark Pharmaceuticals Limited Glenmark Impex L.L.C. Wholly owned subsidiary Sale of goods or services - 14,635.20 0.00 0.00
255 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals South Africa (Pty) Ltd. Wholly owned subsidiary Sale of goods or services - 2,251.10 0.00 0.00
256 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Peru SAC. Wholly owned subsidiary Sale of goods or services - 175.90 0.00 0.00
257 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Thailand) Co. Ltd. Wholly owned subsidiary Sale of goods or services - 57.30 0.00 0.00
258 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Kenya Ltd. Wholly owned subsidiary Sale of goods or services - 2,225.40 0.00 0.00
259 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Colombia Ltda. Wholly owned subsidiary Sale of goods or services - 767.80 0.00 0.00
260 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Mexico, S.A. DE C.V. Wholly owned subsidiary Sale of goods or services - 4,190.80 0.00 0.00
261 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Malaysia Sdn Bhd. Wholly owned subsidiary Sale of goods or services - 3,220.80 0.00 0.00
262 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Inc., USA Wholly owned subsidiary Sale of goods or services - 72,619.10 0.00 0.00
263 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals s.r.o., Czech Republic Wholly owned subsidiary Sale of goods or services - 25,160.40 0.00 0.00
264 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Europe Ltd. Wholly owned subsidiary Sale of goods or services - 20,580.80 0.00 0.00
265 Glenmark Pharmaceuticals Limited Glenmark Pharmaceutical FZE UAE Wholly owned subsidiary Sale of goods or services - (109.40) 0.00 0.00
266 Glenmark Pharmaceuticals Limited GLENMARK GENERICS S.A. Wholly owned subsidiary Sale of goods or services - 134.50 0.00 0.00
267 Glenmark Pharmaceuticals Limited GLENMARK PHARMACEUTICALS ECUADOR S. Wholly owned subsidiary Sale of goods or services - 531.90 0.00 0.00
268 Glenmark Pharmaceuticals Limited Glenmark Therapeutics Inc., USA Wholly owned subsidiary Sale of goods or services - 219.70 0.00 0.00
269 Glenmark Pharmaceuticals Limited Glenmark Ukrain LLC Wholly owned subsidiary Sale of goods or services - 167.10 0.00 0.00
270 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Canada Inc., Canada Wholly owned subsidiary Sale of goods or services - 4,898.00 0.00 0.00
271 Glenmark Pharmaceuticals Limited Glenmark Healthcare Limited Wholly owned subsidiary Sale of goods or services - 10.60 0.00 0.00
272 Glenmark Pharmaceuticals Limited Glenmark Consumer Care Limited Wholly owned subsidiary Sale of goods or services - 7,029.20 0.00 0.00
273 Glenmark Pharmaceuticals Limited Glenmark Specialty S.A. Wholly owned subsidiary Sale of goods or services - 23,583.20 0.00 0.00
274 Glenmark Pharmaceuticals Limited Glenmark Specialty S.A. Wholly owned subsidiary Any other transaction Other Operating Income - 6,668.30 0.00 0.00
275 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Inc. Wholly owned subsidiary Any other transaction Other Operating Income - 5,156.80 0.00 0.00
276 Glenmark Pharmaceuticals Limited Glenmark Healthcare Limited Wholly owned subsidiary Sale of fixed assets - 0.10 0.00 0.00
277 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Inc Wholly owned subsidiary Purchase of goods or services - 36,842.80 0.00 0.00
278 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Inc Wholly owned subsidiary Purchase of goods or services - 1,501.20 0.00 0.00
279 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals FZE. Wholly owned subsidiary Purchase of goods or services - 8,331.20 0.00 0.00
280 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Europe Ltd. Wholly owned subsidiary Purchase of goods or services - 1,435.00 0.00 0.00
281 Glenmark Pharmaceuticals Limited Glenmark Impex L.L.C. Wholly owned subsidiary Purchase of goods or services - 6,338.10 0.00 0.00
282 Glenmark Pharmaceuticals Limited GLENMARK PHILIPPINES INC Wholly owned subsidiary Purchase of goods or services - 104.10 0.00 0.00
283 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals s.r.o. Wholly owned subsidiary Purchase of goods or services - 13,381.40 0.00 0.00
284 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Canada Inc. Wholly owned subsidiary Purchase of goods or services - 43.20 0.00 0.00
285 Glenmark Pharmaceuticals Limited Glenmark Specialty S.A. Wholly owned subsidiary Purchase of goods or services - 1,307.80 0.00 0.00
286 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Kenya Limited Wholly owned subsidiary Purchase of goods or services - 64.00 0.00 0.00
287 Glenmark Pharmaceuticals Limited Glenmark Singapore Pte Ltd Wholly owned subsidiary Purchase of goods or services - 485.20 0.00 0.00
288 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Australia Wholly owned subsidiary Purchase of goods or services - 520.30 0.00 0.00
289 Glenmark Pharmaceuticals Limited Glenmark Ukraine LLC Wholly owned subsidiary Purchase of goods or services - 80.40 0.00 0.00
290 Glenmark Pharmaceuticals Limited IGI Therapeutics SA Wholly owned subsidiary Purchase of goods or services - (17.90) 0.00 0.00
291 Glenmark Pharmaceuticals Limited Glenmark Healthcare Ltd Wholly owned subsidiary Purchase of goods or services - 32.90 0.00 0.00
292 Glenmark Pharmaceuticals Limited Glenmark Consumer Care Ltd Wholly owned subsidiary Purchase of goods or services - 121.10 0.00 0.00
293 Glenmark Pharmaceuticals Limited Glenmark Consumer Care Ltd Wholly owned subsidiary Any other transaction Royalty - 108.20 0.00 0.00
294 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Inc Wholly owned subsidiary Any other transaction Purchase of Tangibles/Capex - 36.10 0.00 0.00
295 Glenmark Pharmaceuticals Limited Glenmark Consumer Care Ltd Wholly owned subsidiary Investment - 5.00 0.00 0.00
296 Glenmark Pharmaceuticals Limited Glenmark Healthcare Ltd Wholly owned subsidiary Loan - 573.50 0.00 0.00
297 Glenmark Pharmaceuticals Limited Glenmark Consumercare Ltd Wholly owned subsidiary Loan - 1,000.00 0.00 0.00
298 Glenmark Pharmaceuticals Limited Glenmark Holding S.A Wholly owned subsidiary Any other transaction Loan repaid by - 13,197.70 0.00 0.00
299 Glenmark Pharmaceuticals Limited Glenmark Consumercare Ltd Wholly owned subsidiary Any other transaction Amount receivable against sale of Business - 24,415.50 0.00 0.00
300 Glenmark Pharmaceuticals Limited Glenmark Holding S.A., Switzerland Wholly owned subsidiary Interest received - 8,195.40 0.00 0.00
301 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Kenya Ltd, Kenya Wholly owned subsidiary Interest received - 81.20 0.00 0.00
302 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Thailand) Co Ltd Wholly owned subsidiary Interest received - 3.70 0.00 0.00
303 Glenmark Pharmaceuticals Limited Glenmark Pharmacuticals Australia Wholly owned subsidiary Interest received - 24.40 0.00 0.00
304 Glenmark Pharmaceuticals Limited Glenmark Healthcare Ltd Wholly owned subsidiary Interest received - 152.20 0.00 0.00
305 Glenmark Pharmaceuticals Limited Glenmark Consumer Care Limited Wholly owned subsidiary Interest received - 29.90 0.00 0.00
306 Glenmark Pharmaceuticals Limited Glenmark Holding S.A., Switzerland Wholly owned subsidiary Any other transaction Other Income - 137.30 0.00 0.00
307 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals s.r.o., Czech Republic Wholly owned subsidiary Any other transaction Other Income - 8.20 0.00 0.00
308 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Inc., USA Wholly owned subsidiary Any other transaction Other Income - 146.20 0.00 0.00
309 Glenmark Pharmaceuticals Limited Glenmark Foundation Other related party Any other transaction CSR Contribution - 573.00 0.00 0.00
310 Glenmark Pharmaceuticals Limited Glenmark Aquatic Foundation Other related party Any other transaction CSR Contribution - 566.00 0.00 0.00
311 Glenmark Pharmaceuticals Limited Mr. Glenn Saldanha Chairman & Managing Director (Promoter) Remuneration - 4,315.20 0.00 0.00
312 Glenmark Pharmaceuticals Limited Mrs. Cherylann Pinto Executive Director (Promoter) Remuneration - 547.10 0.00 0.00
313 Glenmark Pharmaceuticals Limited Mrs. Blanche Saldanha Non Executive Director (Promoter) Any other transaction Sitting Fees - 2.00 0.00 0.00
314 Glenmark Pharmaceuticals Limited Glenmark Arzneimittel GmbH Wholly owned subsidiary Any other transaction Payable - 0.00 2,431.90 2,519.60
315 Glenmark Pharmaceuticals Limited Glenmark Farmaceutica Ltda. Wholly owned subsidiary Any other transaction Receivable - 0.00 7,401.40 13,970.40
316 Glenmark Pharmaceuticals Limited Glenmark Philippines Inc., Philippines Wholly owned subsidiary Any other transaction Receivable - 0.00 5,041.40 3,666.90
317 Glenmark Pharmaceuticals Limited Glenmark Therapeutics Inc., USA Wholly owned subsidiary Any other transaction Receivable - 0.00 1,535.10 1,836.40
318 Glenmark Pharmaceuticals Limited IGI Therapeutics SA Wholly owned subsidiary Any other transaction Receivable - 0.00 16,614.40 3,343.50
319 Glenmark Pharmaceuticals Limited Glenmark Holding S.A., Switzerland(Loan given) Wholly owned subsidiary Any other transaction Receivable - 0.00 5,27,632.00 5,48,309.00
320 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Nigeria) Ltd., Nigeria Wholly owned subsidiary Any other transaction Receivable - 0.00 3,314.10 3,314.10
321 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Nigeria) Ltd., Nigeria(Loan given) Wholly owned subsidiary Any other transaction Receivable - 0.00 1,152.60 1,152.60
322 Glenmark Pharmaceuticals Limited Glenmark Impex L.L.C., Russia Wholly owned subsidiary Any other transaction Receivable - 0.00 16,413.50 7,402.00
323 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals South Africa (Pty) Ltd., South Africa Wholly owned subsidiary Any other transaction Receivable - 0.00 7,490.90 6,143.10
324 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals FZE., United Arab Emirates Wholly owned subsidiary Any other transaction Payable - 0.00 3,414.20 8,615.90
325 Glenmark Pharmaceuticals Limited Glenmark Generics SA., Argentina Wholly owned subsidiary Any other transaction Receivable - 0.00 407.00 568.80
326 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Venezuela., C.A , Venezuela Wholly owned subsidiary Any other transaction Receivable - 0.00 15,582.00 15,582.00
327 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Malaysia Sdn.Bhd., Malaysia Wholly owned subsidiary Any other transaction Receivable - 0.00 3,660.00 3,328.90
328 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Peru SAC., Peru Wholly owned subsidiary Any other transaction Receivable - 0.00 213.90 219.60
329 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Europe Ltd U.K. (Glenmark Generics (Europe) Ltd. Wholly owned subsidiary Any other transaction Receivable - 0.00 824.80 2,016.90
330 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Inc., USA Wholly owned subsidiary Any other transaction Payable - 0.00 84,211.30 71,914.50
331 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals s.r.o., Czech Republic Wholly owned subsidiary Any other transaction Receivable - 0.00 17,341.30 19,623.50
332 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals SK, s.r.o., Slovak Republic Wholly owned subsidiary Any other transaction Payable - 0.00 0.10 0.10
333 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals SP� z.o.o. Wholly owned subsidiary Any other transaction Payable - 0.00 1.60 1.60
334 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Thailand) Co. Ltd., Thailand Wholly owned subsidiary Any other transaction Receivable - 0.00 697.60 432.10
335 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Thailand) Co. Ltd., Thailand (Loan given) Wholly owned subsidiary Any other transaction Receivable - 0.00 182.10 196.30
336 Glenmark Pharmaceuticals Limited Glenmark Uruguay S.A., Uruguay Wholly owned subsidiary Any other transaction Payable - 0.00 8,826.70 9,328.70
337 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Colombia Ltda., Colombia Wholly owned subsidiary Any other transaction Receivable - 0.00 996.20 1,624.10
338 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Kenya Ltd; Kenya Wholly owned subsidiary Any other transaction Receivable - 0.00 17,137.20 18,951.30
339 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Kenya Ltd; Kenya (Loan Given) Wholly owned subsidiary Any other transaction Receivable - 0.00 1,810.20 1,984.80
340 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Mexico S.A. DE C.V. Mexico Wholly owned subsidiary Any other transaction Receivable - 0.00 8,304.20 13,094.80
341 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Egypt S.A.E., Egypt(Loan given) Wholly owned subsidiary Any other transaction Receivable - 0.00 1,080.30 1,141.80
342 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Canada Inc. Wholly owned subsidiary Any other transaction Receivable - 0.00 4,153.70 7,229.40
343 Glenmark Pharmaceuticals Limited Glenmark Specialty S.A. Wholly owned subsidiary Any other transaction Receivable - 0.00 20,171.70 26,921.20
344 Glenmark Pharmaceuticals Limited Glenmark Ukraine LLC Wholly owned subsidiary Any other transaction Receivable - 0.00 4,207.50 4,676.70
345 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Ecuador S.A. Wholly owned subsidiary Any other transaction Receivable - 0.00 600.30 726.70
346 Glenmark Pharmaceuticals Limited GLENMARK PHARMACEUTICALS SINGAPORE Wholly owned subsidiary Any other transaction Payable - 0.00 555.80 804.80
347 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Australia) Wholly owned subsidiary Any other transaction Receivable - 0.00 859.50 758.70
348 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Australia)(loan) Wholly owned subsidiary Any other transaction Receivable - 0.00 0.00 1,505.20
349 Glenmark Pharmaceuticals Limited Glenmark Consumer Care Ltd Wholly owned subsidiary Any other transaction Receivable - 0.00 0.00 28,051.80
350 Glenmark Pharmaceuticals Limited Glenmark Healthcare Ltd Wholly owned subsidiary Any other transaction Receivable - 0.00 3,349.00 4,082.40
351 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Mexico S.A. DE C.V. Mexico Wholly owned subsidiary Any other transaction Receivable - 0.00 917.10 917.10
352 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Peru SAC. Wholly owned subsidiary Any other transaction Receivable - 0.00 0.00 0.10
353 Ichnos Glenmark Innovation Inc. Ichnos Glenmark innovation Therapeutics SA Wholly owned subsidiary Loan - 0.00 13,940.60 0.00 Loan 5.00 Long Term Unsecured Operating Expenses
354 Ichnos Glenmark Innovation Inc. Ichnos Glenmark innovation Therapeutics SA Wholly owned subsidiary Investment - 0.00 85,032.00 85,032.00
355 Ichnos Glenmark Innovation Inc. Ichnos Glenmark innovation Therapeutics SA Wholly owned subsidiary Interest received - 138.90 0.00 0.00
356 Ichnos Glenmark Innovation Inc. Ichnos Glenmark innovation Therapeutics SA Wholly owned subsidiary Any other transaction Other Income - 8,364.10 24,263.50 24,832.70
357 Ichnos Glenmark Innovation Inc. Ichnos Glenmark innovation Therapeutics SA Wholly owned subsidiary Any other transaction Expenses reimbursed - 5.40 0.00 0.00
358 Ichnos Glenmark Innovation Inc. Ichnos Glenmark innovation Therapeutics SA Wholly owned subsidiary Dividend received - 3,88,652.00 0.00 0.00
359 Ichnos Glenmark Innovation Inc. Glenmark Holding S.A. Wholly owned subsidiary Any other transaction Issue of Share capital - 0.00 829.20 829.20
360 Ichnos Glenmark Innovation Inc. Glenmark Holding S.A. Wholly owned subsidiary Any other transaction Issue of Share Premium - 0.00 4,30,407.60 4,30,407.60
361 Ichnos Glenmark Innovation Inc. Glenmark Holding S.A. Wholly owned subsidiary Any other transaction Dividend Payable - 0.00 1,68,903.60 10,174.50
362 Ichnos Glenmark Innovation Inc. Glenmark Holding S.A. Wholly owned subsidiary Any other transaction Dividend declared - 20,879.90 0.00 0.00
363 Ichnos Glenmark Innovation Inc. Glenmark Holding S.A. Wholly owned subsidiary Any other transaction Interest Paid - 4.80 0.00 0.00
364 Ichnos Glenmark Innovation Inc. Glenmark Holding S.A. Wholly owned subsidiary Interest received - 2,826.10 0.00 0.00 Loan 4.00 Long Term Unsecured Operating Expenses
365 Ichnos Glenmark Innovation Inc. Glenmark Holding S.A. Wholly owned subsidiary Loan - 0.00 0.00 1,87,086.00
366 Ichnos Glenmark innovation Therapeutics SA Glenmark Holding S.A. Wholly owned subsidiary Loan - 0.00 5,87,757.90 1,71,547.50
367 Ichnos Glenmark innovation Therapeutics SA Glenmark Holding S.A. Wholly owned subsidiary Interest received - 5,394.40 0.00 0.00
368 Ichnos Glenmark innovation Therapeutics SA Glenmark Speciality S.A. Wholly owned subsidiary Any other transaction Expenses reimbursed/ Receivable - 40.00 0.00 37.30
369 Ichnos Glenmark innovation Therapeutics SA Glenmark Pharmaceuticals Inc USA Wholly owned subsidiary Any other transaction Expenses reimbursed/payable - 25.20 0.00 26.80
370 Glenmark Pharmaceuticals Limited IGI Therapeutics SA Wholly owned subsidiary Any other transaction Other Operating Income - (13,164.60) 0.00 0.00
371 Glenmark Pharmaceuticals Limited Glenmark Impex L.L.C Wholly owned subsidiary Investment - 0.00 14,356.10 14,356.10
372 Glenmark Pharmaceuticals Limited Glenmark Philippines Inc. Wholly owned subsidiary Investment - 0.00 1,167.00 1,167.00
373 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Malaysia Sdn Bhd Wholly owned subsidiary Investment - 0.00 977.20 977.20
374 Glenmark Pharmaceuticals Limited Glenmark Holding S.A. Wholly owned subsidiary Investment - 0.00 14,32,317.50 14,32,317.50
375 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Australia) Pty Ltd Wholly owned subsidiary Investment - 0.00 1,017.20 1,017.20
376 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Egypt S.A.E. Wholly owned subsidiary Investment - 0.00 4,217.40 6,342.70
377 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals FZE Wholly owned subsidiary Investment - 0.00 129.20 129.20
378 Glenmark Pharmaceuticals Limited Glenmark Dominicana SRL Wholly owned subsidiary Investment - 0.00 2.30 2.30
379 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Kenya Ltd Wholly owned subsidiary Investment - 0.00 971.80 971.80
380 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Colombia SAS, Colombia Wholly owned subsidiary Investment - 0.00 5,774.70 5,774.70
381 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Peru SAC Wholly owned subsidiary Investment - 0.00 8,277.90 8,277.90
382 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Mexico, S.A. DE C.V. Wholly owned subsidiary Investment - 0.00 16,952.90 16,952.90
383 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Europe Ltd., U.K. Wholly owned subsidiary Investment - 0.00 5,782.30 5,782.30
384 Glenmark Pharmaceuticals Limited Glenmark South Africa (pty) Ltd Wholly owned subsidiary Investment - 0.00 10,442.00 10,442.00
385 Glenmark Pharmaceuticals Limited Glenmark Uruguay S.A. Wholly owned subsidiary Investment - 0.00 7,745.30 7,745.30
386 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Thailand) Co. Ltd Wholly owned subsidiary Investment - 0.00 37.20 37.20
387 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Ecuador S.A. Wholly owned subsidiary Investment - 0.00 2,454.90 2,454.90
388 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Singapore Pte. Ltd. Wholly owned subsidiary Investment - 0.00 327.30 327.30
389 Glenmark Pharmaceuticals Limited Glenmark Healthcare Limited Wholly owned subsidiary Investment - 0.00 905.00 905.00
390 Glenmark Pharmaceuticals Limited Glenmark Consumer Care Limited Wholly owned subsidiary Investment - 0.00 5.00 5.00
391 Glenmark Pharmaceuticals Limited Glenmark Generics SA., Argentina Wholly owned subsidiary Purchase of goods or services - 99.70 0.00 0.00
Total value of transaction during the reporting period 12,76,860.80